RT RYAN SΞAN ADAMS - rsa.eth 🦄 (@RyanSAdams)this is called a buying opportunity ...

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Headquartered in Charlotte, N.C., Coca-Cola Consolidated (NASDAQ: COKE ) is the largest Coca-Cola bott ...

We had Michael Schumer on yesterday and he said oil is the main impact on the markets. As long as oil remains, obviously we don't want World War II. Uh but in terms of this conflict, as soon as oil shoots up, that's when the markets get impacted.We didn't see that. We haven't seen that. Doesn't look like we're going to see that at least for now.No. And you know, we talk about this all the time. Steve brings it up.Geopolitical bounces in oil are typically short-lived. And I think this is going to be similar ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure:I/we have a beneficial long position in the shares of AVGO either through stock ownership, options, or other derivatives. I wrote this article mysel ...

Core Insights - The article expresses a personal investment perspective, highlighting a long position in Amazon (AMZN) shares, indicating confidence in the company's future performance [2]. Company Analysis - The analyst has a beneficial long position in AMZN, which may suggest a positive outlook on the company's stock performance [2]. - The article emphasizes the importance of conducting personal in-depth research before making investment decisions, reflecting the inherent risks in trading [3]. Industry Context - The analysis is intended for informational purposes only, underscoring the need for investors to perform their own due diligence in the context of market volatility and potential capital loss [3].

The author is presently an entrepreneur and an investor focused on investing in public companies. The author has over ten years of financial services experience, which includes long and short bottoms up fundamental buy-side research, private equity, M and A Advisory, and accounting. See SA policy on anonymous authors: http://seekingalpha.com/page/policy_anonymous_contributors Disclaimer: In no event will the author writing under the pen name Research and Value (hereafter referred to as R&V) or any affiliate ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Core Insights - Chevron reported earnings per share (EPS) that exceeded analyst estimates for the first fiscal quarter, despite a decline in average petroleum prices compared to the same period last year [1] Financial Performance - The company achieved better-than-expected EPS results, indicating strong operational performance [1] - The decline in average petroleum prices suggests a challenging market environment, yet Chevron managed to outperform expectations [1]

Iovance Biotherapeutics’ (NASDAQ: IOVA ) stock collapsed on May 9 after its first‑quarter report revealed a significant earnings miss. The company lost $0.36 per share in Q1 (versus a consensus $0.24 loss), and revenue was $49.3 million, which was well below the $81.53 millionAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my o ...

Pro-Dex, Inc. ( PDEX ) is a contract manufacturer, primarily designing, developing, and manufacturing surgical devices for the medical device industry. The stock has been on a wild ride over the last year, trading as high as $70 and as low as $16. Despite a record performance forI am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I writ ...